Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Obesity Management Market Outlook (2023 to 2033)

The obesity management market is expected to expand with a CAGR of 5.2% during the forecast period from 2023 to 2033. The overall market value is projected to grow from US$ 2,095.6 million in 2023 to US$ 3,494.5 million by 2033.

Due to the steep rise in obesity prevalence over the last two decades, the global market is expected to generate significant revenue in the future. The key factors expected to drive the market are:

  • An increase in the obese population
  • An increase in the number of bariatric surgeries
  • An increase in the adoption of online weight loss and weight management programs
  • An increase in disposable income in developing economies
  • Sedentary lifestyle
  • Increased government initiatives to raise awareness among the obese population
Report Attributes or Data Points Details
Global Obesity Management Market Valuation in 2022 US$ 1,994 million
Estimated Global Market Share in 2023 US$ 2,095.6 million
Forecasted Global Market Size by 2033 US$ 3,494.5 million
Projected Global Market Growth Rate from 2023 to 2033 5.2% CAGR
Historical Market Growth Rate from 2018 to 2022 4% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

The Pertinent Windows of Opportunity for Market Participants in the Coming Decade

Obesity affects one in every three adults in North America. Obesity causes a slew of chronic diseases, many of which can be avoided with proper weight management. Obese patients should be treated for the initial stage of hypertension by losing weight through lifestyle changes, pharmacological treatment, and/or bariatric surgery, according to the AHA.

The NHS in the United Kingdom has suggested that weight loss programs educate people about the dangers of obesity and assist obese people in losing weight. People are becoming more aware of their physical appearance.

Elements Curtailing Obesity Management Demand

The high cost of surgeries and drugs may be a barrier to obesity management. Weight loss surgery is not reimbursed favorably in developing countries. Because weight management is a time-consuming process, medical payers are hesitant to provide reimbursement.

Furthermore, concerns about the safety of obesity management drugs are cruising clinical trials, with only a few drugs reaching the market. Drug-induced cardiovascular disease or cancer can be caused by certain drug formulations. These incidents have the potential to result in drug recalls.

The FDA, for example, has requested that Eisai withdraw its weight-loss drug Belviq from the market after clinical trials revealed an increased incidence of cancer in users.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

The Key Determinants are Generating Buzz of Obesity Management

Geriatric population growth in developed countries, primarily due to improved healthcare leading to increased life expectancy, is driving the market. This is because geriatric people are highly susceptible to gaining noticeable body fat while losing muscle mass and functioning ability. As a result, the geriatric population is a critical segment of the market in both the short and long term.

Aside from that, genetics and medication side effects are linked to obesity, which must be handled with the aid of obesity management programs. This helps to fuel the adoption of obesity management services and products.

Comparative View of the Adjacent Obesity Management Market

Obesity Management Market:

Attributes Obesity Management Market
CAGR (2023 to 2033) 5.2%
Market Value (2028) US$ 2,702.8 million
Growth Factor An increasing number of bariatric surgeries are being performed.
Opportunity Online weight loss and weight management programs are becoming more popular.
Key Trends Expanding government initiatives to raise awareness among obese people.

Clinical Alarm Management Market:

Attributes Clinical Alarm Management Market
CAGR (2023 to 2033) 10.4%
Market Value (2028) US$ 5.96 billion
Growth Factor The rising demand for healthcare, as well as the growing patient population, has increased the frequency of patient alarms, regardless of priority.
Opportunity With rising disease prevalence and a growing geriatric population, clinical alarms have the potential to reduce costs and facilitate better patient management, which is a key contributor to market growth.
Key Trends Electronic health records are becoming more popular.

Dietary Fibers Market:

Attributes Dietary Fibers Market
CAGR (2023 to 2033) 12.6%
Market Value (2028) US$ 13.84 billion
Growth Factor The growing elderly population worldwide, combined with increased consumption of fortified food products, has driven the dietary fiber market.
Opportunity Growing health consciousness among consumers worldwide, as well as sensitivity to nutrient-rich products, have been major driving factors in the expansion of the supplement industry.
Key Trends The growing young population across the region, government directives to include fiber-rich foods in daily diets, and rising per-capita income are some of the factors driving Asia Pacific dietary fiber market growth.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Which is the Leading Segment in the Obesity Management Market by Drug Type?

Liraglutide had a notable market share at 32.4%. Liraglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist with a long pharmacokinetic profile that preserves biological activity.

These products promote weight loss by suppressing appetite and energy consumption. GLP-1 receptor agonists can also cause significant weight loss in a short period, which might drive growth in the coming decade.

Which is the Leading Segment in the Obesity Management Market by Surgery Type?

Gastric sleeve surgery will remain dominant in the market during the forecast period, with an estimated 43.5% market share by the end of 2033. Gastric sleeve surgery is very convenient and safe, with excellent patient outcomes.

This procedure induces hormonal changes to aid in weight loss. These hormones not only help with weight loss but also with high blood pressure and heart disease caused by obesity. It is the simplest methodology and requires less time in surgery.

Category By Drug Type
Top Segment Liraglutide
Market Share in Percentage 65.2%
Category By Distribution Channel
Top Segment Hospital Pharmacies
Market Share in Percentage 55.8%

Which is the Leading Segment in the Obesity Management Market by Distribution Channel?

Hospital pharmacies will account for more than 50% of the global distribution channel. Elevated footfall in hospitals for anti-obesity counseling sessions contributes to a large share of market revenue.

Regional Outlook

North America

The United States is expected to maintain a high growth rate throughout the forecast period with a total market share of more than 63.0% in 2022. Obesity is a major health issue in the country, resulting in a variety of diseases. North America is expected to generate significant revenue in the global market in the coming years. Factors like high population awareness, the presence of prominent drug manufacturers, and the rising prevalence of obesity account for the region's rapid growth in this market. The bupropion and naltrexone segment leads the North American market and is likely to sustain its lead, making it highly appealing to stakeholders.

Regional Market Comparison Global Market Share in Percentage
North America 35%
Europe 29.5%

Europe

Europe contributes significantly to the overall market's revenue. Obesity in the region is exacerbated by a high intake of processed meats and a high prevalence of lifestyle diseases. The availability of obesity management health programs and government-led obesity management health centers bodes well for the region's obesity management market growth.

Asia Pacific

Asia Pacific is rapidly emerging as a key market for obesity management. Obesity management programs have emerged as a result of the region's developing countries' excessive rise in obesity incidence as a result of changing lifestyles. This fuels the regional market.

The Propensity for Obesity Management Growth in India

India dominates the South Asian market with a market share of 60.9% and is expected to grow at a CAGR of 4.8%. Rising healthcare expenditures are expected to strengthen the country's market. Obesity among adults is expected to triple between 2010 and 2040, with an estimated 30% of the population being overweight by that time. Obesity is increasing in the country due to increased consumption of energy-dense foods, a sedentary lifestyle, a lack of health care services, and inadequate financial support.

Regional Market Comparison Global Market Share in Percentage
The United States 32.1%
Germany 7%
Japan 4.3%

Germany's Key Growth-Enabling Factors

Germany held nearly 17.6% of the European market in 2022. The Robert Koch Institute reports that 67% of adults in Germany are overweight. Germany has a significant problem with high cholesterol and type 1 diabetes. The German federal government is enacting policies to combat the country's growing obesity problem. In addition, the number of anti-obesity clinics in the country has increased. These factors will contribute to the expansion of obesity management in the country.

Russia’s Obesity Management Market is Financially Viable

With a market value of US$ 36.6 million in 2022, Russia occupies an important financially rewarding position in Europe. Since 2014, the number of Russians diagnosed with obesity has increased by nearly 50%. According to the WHO, more than 60% of Russians are overweight, with 20% being obese. The Russian Health Ministry is constantly striving to create strategies for enhancing the population's overall health. According to the World Factbook, the prevalence of adult obesity in Russia is 23.1%.

The Growth Potential in China's Obesity Management Market

The regional market in China is expanding at a CAGR of 4.3% and is expected to account for more than 42% of the East Asian market over the forecast period. According to national survey data, more than half of all Chinese adults are now overweight or obese. Rapid economic growth in the country in recent decades has resulted in significant changes in lifestyle, diet, and exercise habits. According to the National Health Commission report from 2020, more than half of adults are classified as overweight, with 16.4% being obese.

Regional Markets CAGR (2023 to 2033)
The United Kingdom 5.1%
China 6.6%
India 6.4%
Australia 4.4%

How is the Start-Up Ecosystem in the Obesity Management Market?

Business models evolve sometimes as a result of changes in the obesity management industry, and sometimes as a result of technological advancements, resulting in the emergence of new and exciting market trends.

Standout Market Players You Should Know: Allurion Insights, Apollo Endosurgery, Inc., Obalon Therapeutics, and Glyscend Therapeutics

Launch:

Allurion Insights, a new and powerful addition to the Allurion Virtual Care Suite, was launched today by Allurion Technologies, a pioneering leader in the development of innovative, scalable, and trusted weight loss experiences. Allurion Insights is a weight-loss provider-specific integrated remote patient monitoring and telehealth solution.

Approval:

Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, announced that the US Food and Drug Administration (FDA) has approved the ORBERATM Intragastric Balloon to help adult patients with obesity (BMI 30 to 40) lose and maintain weight.

Approval:

Obalon Therapeutics is making its stock market debut with a $75 million IPO to fund the commercialization of its weight loss balloon device in the United States. The product launch comes just a few weeks after Obalon filed for an IPO and revealed that its ingestible weight loss balloon had received FDA PMA approval.

Financing Round:

Glyscend Therapeutics has completed a $20.5 million Series A financing round. The round of funding was led by healthcare investors Brandon Capital Partners, through its Medical Research Commercialisation Fund (MRCF), and Santé Ventures, and will be used to support the development of the company's novel oral polymer therapy for patients with T2D and other metabolic diseases. In 2019, Breakout Labs provided seed funding.

How Competition Influences the Obesity Management Market?

The overall market is relatively consolidated, with only a few leading players competing. Humongous players in this market are involved in Research and Development for product innovation and the development of existing products. GlaxoSmithKline Plc, VIVUS, Inc., Novo Nordisk A/S, Currax Pharmaceuticals LLC, Cheplapharm Arzneimittel GmbH, Bausch Health Companies Inc., and Takeda Pharmaceuticals, Inc. are among the prominent companies operating in the global market.

Date January 2018
Company Name H2-Pharma
Strategy Collaboration
Details H2-Pharma announced a collaboration with Cheplapharm Arzneimittel GmbH in January 2018 and re-launched XENICAL® 120 mg capsules through its newly formed branded division.
Date February 2020
Company Name VIVUS, Inc.
Strategy Collaboration
Details VIVUS, Inc. announced in February 2020 that its Korean marketing partner, Alvogen, had launched Qsymia in the Republic of Korea.
Date June 2021
Company Name Novo Nordisk
Strategy FDA approval
Details Novo Nordisk received FDA approval for Wegovy semaglutide injection in adults with at least one weight-related condition in June 2021.

Key Players Profiled in the Global Market

  • GlaxoSmithKline Plc.
  • VIVUS, Inc.
  • Novo Nordisk A/S
  • Currax Pharmaceuticals LLC
  • Cheplapharm Arzneimittel GmbH
  • Bausch Health Companies Inc.
  • Takeda Pharmaceuticals, Inc.

Key Segmentation

By Drug Type:

  • Bupropion and Naltrexone
  • Orlistat
  • Lorcaserin
  • Phentermine and Topiramate
  • Liraglutide

By Surgery Type:

  • Gastric Bypass Surgery
  • Adjustable Gastric Banding Surgery
  • Gastric Sleeve Surgery
  • Duodenal Switch Surgery
  • Others

By Distribution Channel:

  • Hospitals Pharmacies
  • Retail Pharmacies
  • E-commerce

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • The Middle East & Africa (MEA)
  • Europe

Frequently Asked Questions

What is the Projected Growth Forecast of the Obesity Management Market?

The market is expected to develop a CAGR of 5.2% through 2033.

How was the Historical Performance of the Market?

The market recorded a 4% CAGR from 2018 to 2022.

What is the Current Market Valuation of the Obesity Management Market?

The market is estimated to secure a valuation of US$ 2,095.6 million in 2023.

Which Region Holds a Significant Share of the Obesity Management Market?

North America is leading the market, with a share of 35%.

Which Countries Dominate the Global Market?

The United States, Japan, and Germany dominate the global market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        5.3.1. Bupropion and Naltrexone

        5.3.2. Orlistat

        5.3.3. Lorcaserin

        5.3.4. Phentermine and Topiramate

        5.3.5. Liraglutide

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Surgery Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Surgery Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Surgery Type, 2023 to 2033

        6.3.1. Gastric Bypass Surgery

        6.3.2. Adjustable Gastric Banding Surgery

        6.3.3. Gastric Sleeve Surgery

        6.3.4. Duodenal Switch Surgery

        6.3.5. Others

    6.4. Y-o-Y Growth Trend Analysis By Surgery Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Surgery Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033

        7.3.1. Hospitals Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. E-commerce

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Drug Type

        9.2.3. By Surgery Type

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Surgery Type

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Type

        10.2.3. By Surgery Type

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Surgery Type

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Drug Type

        11.2.3. By Surgery Type

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Surgery Type

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Drug Type

        12.2.3. By Surgery Type

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Surgery Type

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Drug Type

        13.2.3. By Surgery Type

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Surgery Type

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug Type

        14.2.3. By Surgery Type

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Surgery Type

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Type

        15.2.3. By Surgery Type

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Type

        15.3.3. By Surgery Type

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Type

            16.1.2.2. By Surgery Type

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Type

            16.2.2.2. By Surgery Type

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Type

            16.3.2.2. By Surgery Type

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Type

            16.4.2.2. By Surgery Type

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Type

            16.5.2.2. By Surgery Type

            16.5.2.3. By Distribution Channel

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Type

            16.6.2.2. By Surgery Type

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Type

            16.7.2.2. By Surgery Type

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Type

            16.8.2.2. By Surgery Type

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Type

            16.9.2.2. By Surgery Type

            16.9.2.3. By Distribution Channel

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Type

            16.10.2.2. By Surgery Type

            16.10.2.3. By Distribution Channel

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Type

            16.11.2.2. By Surgery Type

            16.11.2.3. By Distribution Channel

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Type

            16.12.2.2. By Surgery Type

            16.12.2.3. By Distribution Channel

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Type

            16.13.2.2. By Surgery Type

            16.13.2.3. By Distribution Channel

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Type

            16.14.2.2. By Surgery Type

            16.14.2.3. By Distribution Channel

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Type

            16.15.2.2. By Surgery Type

            16.15.2.3. By Distribution Channel

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Type

            16.16.2.2. By Surgery Type

            16.16.2.3. By Distribution Channel

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Type

            16.17.2.2. By Surgery Type

            16.17.2.3. By Distribution Channel

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Type

            16.18.2.2. By Surgery Type

            16.18.2.3. By Distribution Channel

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Type

            16.19.2.2. By Surgery Type

            16.19.2.3. By Distribution Channel

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Type

            16.20.2.2. By Surgery Type

            16.20.2.3. By Distribution Channel

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Type

            16.21.2.2. By Surgery Type

            16.21.2.3. By Distribution Channel

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Drug Type

            16.22.2.2. By Surgery Type

            16.22.2.3. By Distribution Channel

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2022

            16.23.2.1. By Drug Type

            16.23.2.2. By Surgery Type

            16.23.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Type

        17.3.3. By Surgery Type

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. GlaxoSmithKline Plc.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. VIVUS, Inc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Novo Nordisk A/S

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Currax Pharmaceuticals LLC

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Cheplapharm Arzneimittel GmbH

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Bausch Health Companies Inc.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Takeda Pharmaceuticals, Inc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Pfizer Inc

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. F. Hoffmann-La Roche Ltd

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. AstraZeneca

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. Herbalife Ltd.

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Pediatric Obesity Management Market

Published : February 2023

Explore Healthcare Insights

View Reports

Obesity Management Market